The role of adenosine a2a receptors in antidepressant activity in an experimental animal model of depression

• Authors: Anna DZIUBINA , Małgorzata ZYGMUNT , Barbara FILIPEK , Kinga SAŁAT , Adrian BRYŁA , Tadeusz LIBROWSKI , Joanna GDULA-ARGASIŃSKA
• Languages of publication: EN

Abstracts

EN

Intensive studies on the role of adenosine A2A receptors in Parkinson’s disease have been carried out for many years,. These studies have indicated that the antagonists of these receptors not only alleviate motor deficits but also exhibit neuroprotective effects in various animal models. Little is known about the role of these receptors in ailments accompanying Parkinson’s disease, such as depression and anxiety. This paper provides a summary of existing research on the role of A2A receptors in comorbid depression in Parkinson’s disease.

Keywords

EN

A2A receptor; Parkinson’s disease; adenosine; antidepressant activity; depression

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: ZOZ Ośrodek UMEA SHINODA-KURACEJO
• Journal: Medicina Internacia Revuo
• Year: 2017
• Volume: 28
• Issue: 109
• Pages: 228-236

Contributors

author

Anna DZIUBINA

author

Małgorzata ZYGMUNT

• Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University, Medical College, Medyczna 9, 30-688 Cracow, Poland

author

Barbara FILIPEK

author

Kinga SAŁAT

author

Adrian BRYŁA

author

Tadeusz LIBROWSKI

author

Joanna GDULA-ARGASIŃSKA

References

• 1. Chen, J-F., Sonsalla, P.K., Pedata, F., Melani, A., Domenici, M.R., Popoli, P.; Prog Neurobiol, 2007, 83, 310–331.\
• 2. Pytka, K., Zygmunt, M., Filipek, B.; Postepy Hig Med Dosw, 2013, 67, 700–708.
• 3. Shen, H-Y., Chen, J.F.; Current Neuropharmacol, 2009, 7, 195–206.
• 4. Kadowaki, H.T., Kobayashi, M., Mori, A., Jenner, P., Kanda, T.; Psychopharmacol, 2013, 230, 345– 352.
• 5. Pinna, A.; Exp Opin Investig Drugs, 2009, 18,1619–1631.
• 6. Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Linden, J., Müller, Ce.; Pharmacol Rev, 2011, 63, 1–33.
• 7. Dixon, A.K., Gubitz, A.K., Sirinathsinghji, D.J., Richardson, P.J., Freeman, T.C.; Br J Pharmacol, 1996, 118(6), 1461–1468.
• 8. Berck, M., Plein, H., Ferreira, D., Jersky, B.; Eur. Neuropsychopharmacology 2001, 11, 183–186.
• 9. Porsolt, R.D., Le Pchon, M., Jalfre, M.; Nature, 1978, 266, 730–732.
• 10. Kaster, M.P., Rosa, A.O., Rosso, M.M., Goulart, E.C., Santos, A.R., Rodrigues, A.L.; Neurosci Lett, 2004, 355, 21–24.
• 11. Kaster, M.P., Budni, J., Santos, A.R., Rodrigues, A.L.; Eur J Pharmacol, 2007, 576, 91–98.
• 12. Kaster, M.P., Rosa, A.O., Santos, A., Rodrigues, A.L.; Int J Neuropsychopharmacol, 2005, 8, 601– 606.
• 13. Gołembiowska, K., Dziubina, A.; Naunyn Schmiedebergs Arch Pharmacol, 2001, 363, 663– 670.
• 14. Pellicano, C., Wu, K., Loane, C., Turkheimer, F.E., Molly, S., Brooks, D.J.; Neuropsychiat Dis Treat, 2007, 3, 145–151.
• 15. Palhagen, S.E., Carlsson, M., Curman, E., Walinde, J., Granerus, A.K..; Acta Neurol Scand, 2008,117, 295–304.
• 16. Lieberman, A.; Acta Neurol Scand, 2006, 113, 1–8.
• 17. Kuopio, A.M., Marttila, R.J., Toivonen, M., Rinne, U.K.; Mov Disord, 2000, 15, 216–223.
• 18. Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., Henn, F.; J Neurol, 2010, 257, 1073–1082.
• 19. Groenewegen, H.J.; CNS Spectr, 2007, 12, 887–892.
• 20. Kuter, K., Kolasiewicz, W., Gołembiowska, K., Dziubina, A., Schulze, G., Berghauzen, K.; Pharmacol Rep, 2011, 63,1383–1392.
• 21. Brown, A.S., Gershon, S.; J Neural Transm Gen Sect, 1993, 1, 75–109.
• 22. Hesse, S., Meyer, P.M., Strecker, K., Bartel, H., Wegner, F., Oehlwein, C.; Eur J Nucl Med Mol Imaging, 2009, 36, 428–435.
• 23. Remy, P., M. Doder, A. Lees, N. Turjanski, And D. Brooks.; 2005, 128, 1314–1322.
• 24. Joutsa, J., Rinne, J.O., Eskola, O., Kaasinen, V.; J Parkinsons Dis, 2013, 3, 325–329.
• 25. Mayeux, R., Stern, Y., Cote, L., Williams, J.B.; Neurology, 1984, 34, 642–646.
• 26. Pollitis, M., Wu, K., Loane, C., Turkheimer, F.E., Molly, S., Brooks, D.J.; Neurology, 2010, 75, 1920–27.
• 27. Kostić, V.S., Agosta, F., Galantucci, S., Spica, V., Jecmenica-Lukic, M.; Neurology, 2010, 75, 857– 863.
• 28. Chagas, M.H.N., Linares, I.M.P., Garcia, G.J., Hallak, J.E.C., Tumas, V., Crippa, J.A.S.; Int Psychogeriatr, 2013, 2,1–9.
• 29. Hemmerle, A.M., Herman, J.P., Seroogy, K.B.; Exp Neurol, 2012, 233, 79–86.
• 30. Müller, T., Welnic, J., Muhlack, S.; J Neural Transm, 2007, 114, 347–350.
• 31. Huber, T.; Pharmacopsychiatry, 1999, 32, 47–55.
• 32. Leentjens, A.F.; Drugs, 2011, 71, 273–286.
• 33. Leentjens, A.F., Vreeling, F.W., Luijckx, G.J., Verhy, F.R.; Int J Geriatr Psychiatry, 2003, 18, 552–554.
• 34. Ceravolo, R., Nuti, A., Piccinni, A., Dell’agnello, G., Bellini, G., Gambaccini, G.; Neurology, 2000, 55, 1216–1218.
• 35. Andersen, J., Aabro, V., Gulmann, N., Hjelmsted, A., Pedersen, H.E.; Acta. Neurol. Scand. 1980, 62, 210–219.
• 36. El Yacoub, M., Costentin, J., Vaugeois, J.M.; Neurology, 2003, 61, 82–87.
• 37. Bogenpohl, J.W., Ritter, S. L., Hall, R.A., Smith. Y.; J Comp Neurol, 2012, 520, 570–589.
• 38. Rosin, D.L., Robeva, A., Woodard, R.L., Guyenet, P.G., Linden, J.; J Comp Neurol, 1998, 401, 163–186.
• 39. Fink, J.S., Weaver, D.R., Rivkees, S.A., Peterfreund, R.A., Pollack, A.E. Adler, E.M.; Mol Brain Res, 1992, 14, 186–195.
• 40. Xu, K., Bastia, E., Schwarzschild, M.; Pharmacol Ther, 2005, 105, 267–310.
• 41. Lerner, T.N., Horne, E.A., Stella, N., Kreitzer, A.C.; J Neurosci, 2010, 30, 2160–64.
• 42. Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M.E., Mallol, J., Canela, E.I., Zoli, M., Agnati, L.F., Ibanez, C.F., Lluis, C., Franco, R., Ferre, S., Fuxe, K.; J Biol Chem, 2002, 277, 18091– 18097.
• 43. Gołembiowska, K., Dziubina, A.; Brain Res, 2004, 298, 208–217.
• 44. Kurokawa, M., I.P. Kirk, K.A. Kirkpatrick, H. Kase, And P.J. Richardson.; Br J Pharmacol, 1994, 113, 43–48.
• 45. Ledent, C., Vaugeosis, J.M., Schiffmann, S.N., Pedrazzini, T., El Yacoubi, M.; Nature, 1997, 388, 674–678.
• 46. Crema, L.M., Pettenuzzo, L.F., Schlabitz, M., Diehl, L., Hoppe, J., Mestriner, R., Laureano, D., Salbego, C., Dalmaz, C., Vendite, D.; Physiol Behav, 2013, 109, 1–7.
• 47. Rasheed, N., Ahmad, A., Pandey, C.P., Chaturvedi, R.K., Lohani, M., Palit, G.;Neurochem Res, 2010, 35, 22–32.
• 48. Okada, M., Nutt, D.J., Murakami, T., Zhu, G., Kamata, A., Kawata Y.; J Neurosci, 2001, 21, 628– 640.
• 49. Batalha,V.L., Pego, J.M., Fontinha, B.M., Costenla, A.R., Valadas, J.S., Baqi, Y.; Mol. Psych. 2013, 18, 320–331.
• 50. Chen, B., Dowlatshahi, D., Macqueen, G.M., Wang, J.F., Young, L.T.; Biol Psychiatry, 2001, 50, 260–265.
• 51. Shirayama, Y., Chen, A.C., Nakagawa, S., Russel, D.S., Duman, R.S.; J Neurosci, 2002, 22, 3251–3261.
• 52. Sebastiao, A.M., Ribeiro, J.A.; Br J Pharmacol, 2009, 158, 15–22.
• 53. Potenza, R.L., Tebano, M.T., Martire, A., Domenici, M.R., Pepponi, R., Armida, M.; Purinergic Signal, 2007, 3, 333–338.
• 54. Jeon, S.J., Rhee, S.Y., Ryu, J.H., Cheong, J.H., Kwon, K., Yang, S.I.; Neurochem Res, 2011, 36, 2259–2269.
• 55. Tebano, M.T., Martire, A., Potenza, R.L.; J Neurochem, 2008, 104, 279–286.
• 56. Shook, B.C., Jackson, P.F.; ACS Chem Neurosci, 2011, 2, 555–567.
• 57. Ochi, M., Koga, K., Kurokawa, M., Kase, H.,
• Nakamura, J., Kuwana, Y.; Neuroscience, 2000, 100, 53–62.
• 58. Trevitt, J., Vallance, Ch., Harris, A., Goode, T.; Pharmacol Biochem Behav, 2009, 92, 521–527.
• 59. Kanda, T., Jackson, M.J., Smith, L.A., Pearce, R.K., Nakamura, J., Kase, H.; Exp Neurol, 2000, 162, 321–327.
• 60. Bibbiani, F., Oh, J.D., Petzer, J.P., Castagnoli, N.Jr., Chen, J.F., Schwarzschild, M.A.; Exp Neurol, 2003, 184, 285–294.
• 61. Morelli, M., Di Paolo, T., Wardas, J., Calon, F., Xiao, D., Schwarzschild, M.A.; Prog Neurobiol, 2007, 83, 293–309.
• 62. Pinna, A., Pontis, S., Borsini, F., Morelli, M.; Synapse, 2007, 61, 606–614.
• 63. Hodgson, R.A., Bedard, P.J., Varty, G.B., Kazdoba, T.M., Di Paolo, T., Grzelak, M.E.; Exp Neurol, 2010, 225, 384–390.
• 64. Simola, N., Fenu, S., Baraldi, P.G., Tabrizi, M.A., Morelli, M.; Exp Neurol, 2004, 1, 182–188.
• 65. Sarges, R., Howard, H.R., Browne, R.G., Lebel, L.A., Seymour, P.A., Koe, B.K.; J Med Chem, 1990, 33, 2240–2254.
• 66. Yamada, K., Kobayashi, M., Mori, A., Jenner, P., Kanda, T.; Pharmacol Biochem Behav, 2013, 114- 115, 23–30.
• 67. Hodgson, R.A., Bertorelli, R., Varty, G.B., Lachowicz, J.E., Forlani, A., Fredduzzi, S.; J Pharmacol Exp Ther, 2009, 330, 294–303.
• 68. Gołembiowska, K., Dziubina, A.; Neuropharmacology, 2004, 47, 414–426.
• 69. Yamada, K., Kobayashi, M., Shiozaki, S., Ohta, T., Mori, A., Jenner, P.; Psychopharmacology, 2014, 231, 2839–2849.
• 70. Kano, O., Ikeda, K., Kiyozuka, T., Iwamato, K., Ito, H., Kawase, Y.; Neuropsychiatr Dis Treat, 2000, 4, 707–710.
• 71. Pechlivanowa, D.M., Tchekalarova, J.D., Alova, L.H., Petkov, V.N., Rumen, P.Y., Krassimira, S.; Behav Pharmacol, 2012, 23, 339–347

• Document Type: article